Nasus Pharma Ltd. (NSRX) Income Statement
NSRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNSRX revenue and net income
NSRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NSRX quarterly EPS vs estimates
Nasus Pharma beat the analyst EPS estimate in 2 of the last 4 quarters.
NSRX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $2.2M | $335,000 | $567,000 | $1.1M |
| Sales, general & admin | $2.7M | $743,000 | $580,000 | $926,000 |
| Total operating expenses | $4.9M | $1.1M | $1.1M | $2.0M |
| Operating income | −$4.9M | −$1.1M | −$1.1M | −$2.0M |
| Interest expense | — | $29,000 | $49,000 | $18,000 |
| Income before taxes | −$5.8M | −$1.6M | −$1.0M | −$2.2M |
| Net income | −$5.9M | −$1.5M | −$1.1M | −$1.7M |
| EBITDA | −$4.9M | −$1.5M | −$956,000 | −$2.1M |
| EPS (diluted) | −$0.23 | −$0.09 | −$0.15 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $2.6M | $1.3M | $588,952 | $144,500 | $144,500 | $83,500 | $83,500 | $84,000 | $84,000 | $169,000 | $169,000 | $114,500 |
| Sales, general & admin | $3.5M | $1.7M | — | $264,000 | $264,000 | $214,000 | $214,000 | $157,500 | $157,500 | $126,500 | $126,500 | $163,500 |
| Total operating expenses | $6.0M | $3.0M | $1.2M | $408,500 | $408,500 | $297,500 | $297,500 | $241,500 | $241,500 | $295,500 | $295,500 | $278,000 |
| Operating income | −$6.0M | −$3.0M | −$1.2M | −$408,500 | −$408,500 | −$297,500 | −$297,500 | −$241,500 | −$241,500 | −$295,500 | −$295,500 | −$278,000 |
| Income before taxes | −$5.9M | −$3.0M | −$1.4M | −$597,000 | −$597,000 | −$333,500 | −$333,500 | −$442,500 | −$442,500 | −$410,500 | −$410,500 | −$92,000 |
| Net income | −$5.9M | −$3.0M | −$1.4M | −$626,000 | −$626,000 | −$330,500 | −$330,500 | −$435,500 | −$435,500 | −$418,500 | −$418,500 | −$107,000 |
| EBITDA | −$5.9M | — | −$1.2M | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | −$0.54 | — | $0.00 | −$0.14 | — | −$0.09 | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NSRX's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NSRX financial results
Nasus Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $5.9 million. Diluted earnings per share came to −$0.23.
See the NSRX stock overview for the latest quote and news, or the NSRX chart for price history and technical indicators.
NSRX income statement FAQ
Does Nasus Pharma have revenue?
Nasus Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Nasus Pharma profitable?
No. Nasus Pharma reported a net loss of $5.9 million in fiscal 2025.
How much does Nasus Pharma spend on research and development?
Nasus Pharma spent $2.2 million on research and development in fiscal 2025.
What are Nasus Pharma's earnings per share?
Nasus Pharma earned $-0.23 per diluted share in fiscal 2025, compared with $-0.09 a year earlier.
When does Nasus Pharma's fiscal year end?
Nasus Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.